Amgen spin-off Atara Biotherapeutics raises $52m series B funding from investors including Amgen Ventures and Celgene Corporation, to accelerate clinical development of lead programs.
Atara Biotherapeutics, a US-based drug development company which was spun off in 2012 from US-based biotechnology company Amgen, has made a second closing of its series B financing, bringing the total raised to $52m. Investors in the series B include Amgen Ventures, the corporate venture capital fund of Amgen, biopharmaceutical company Celgene Corporation, hedge fund The Baupost Group, and venture capital firms Alexandria Venture Investments, DAG Ventures, Domain Associates, EcoR1 Capital and Kleiner Perkins Caufield & Byers.
Previously, venture capital…
